Vaccibody As Stock Total Asset
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
Vaccibody As fundamentals help investors to digest information that contributes to Vaccibody's financial success or failures. It also enables traders to predict the movement of Vaccibody Stock. The fundamental analysis module provides a way to measure Vaccibody's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaccibody stock.
Vaccibody |
Vaccibody As Company Total Asset Analysis
Vaccibody's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Vaccibody Total Asset | 270.2 M |
Most of Vaccibody's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaccibody As is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, Vaccibody As has a Total Asset of 270.2 M. This is 96.41% lower than that of the Biotechnology sector and 86.32% lower than that of the Health Care industry. The total asset for all Norway stocks is 99.08% higher than that of the company.
Vaccibody Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaccibody's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaccibody could also be used in its relative valuation, which is a method of valuing Vaccibody by comparing valuation metrics of similar companies.Vaccibody is currently under evaluation in total asset category among its peers.
Vaccibody Fundamentals
| Return On Equity | -0.23 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (77.18) % | |||
| Current Valuation | 32.03 M | |||
| Shares Outstanding | 38.55 M | |||
| Shares Owned By Insiders | 3.45 % | |||
| Shares Owned By Institutions | 49.84 % | |||
| Number Of Shares Shorted | 159.22 K | |||
| Price To Earning | 12.63 X | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 2.31 X | |||
| Revenue | 44.7 M | |||
| Gross Profit | 44.7 M | |||
| EBITDA | 869 K | |||
| Net Income | 5.32 M | |||
| Cash And Equivalents | 192.33 M | |||
| Cash Per Share | 5.17 X | |||
| Total Debt | 8.77 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 18.60 X | |||
| Book Value Per Share | 5.64 X | |||
| Cash Flow From Operations | (14.43 M) | |||
| Short Ratio | 0.08 X | |||
| Earnings Per Share | (1.59) X | |||
| Target Price | 9.31 | |||
| Number Of Employees | 33 | |||
| Beta | -0.39 | |||
| Market Capitalization | 192.73 M | |||
| Total Asset | 270.2 M | |||
| Retained Earnings | (103.24 M) | |||
| Working Capital | 200.8 M | |||
| Z Score | 13.71 | |||
| Net Asset | 270.2 M |
About Vaccibody Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaccibody As's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaccibody using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaccibody As based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| S | SentinelOne | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |